BPC-157 and TB-500: why these two peptides are studied together

Two peptides with complementary proposed mechanisms — both awaiting a final FDA decision after the July 2026 advisory committee vote.

TL;DR

• BPC-157 and TB-500 are often discussed together in tissue-repair contexts because their proposed mechanisms address different parts of the repair process: BPC-157 around angiogenesis and matrix-level signaling, TB-500 around actin regulation and cell migration.
• The combination is sometimes referred to as a "RECOVER" protocol concept. It is a research-driven hypothesis, not a validated clinical protocol.
• Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. A physician may prescribe them together when they decide it is appropriate.

What it is

The BPC-157 / TB-500 pairing is one of the most-discussed combinations in peptide-protocol contexts. The rationale, when stated carefully, is mechanistic complementarity: each peptide is proposed to influence a different part of the tissue-repair process, and the hypothesis is that combining them addresses repair more comprehensively than either alone.

How the proposed mechanisms differ

BPC-157's proposed mechanisms center on angiogenesis (new blood vessel formation, supporting blood and oxygen delivery to healing tissue), nitric oxide signaling, growth factor upregulation, and matrix-level tissue repair effects observed in animal models (Sikiric et al., Current Pharmaceutical Design, 2018).

TB-500 (and full Thymosin Beta-4)'s proposed mechanisms center on actin sequestration (regulating cellular shape change and migration), modulation of inflammatory signaling, promotion of cell migration into injury sites, and angiogenic effects in some tissue contexts (Crockford et al., Annals of the New York Academy of Sciences, 2010).

The complementarity argument is straightforward: BPC-157 addresses angiogenic and matrix-level support, TB-500 addresses cellular migration and inflammation modulation. Together — under the hypothesis — they cover more of the repair process than either alone.

The RECOVER protocol concept

In peptide-protocol discussions, this combination is sometimes referred to as a "RECOVER" protocol — a label that captures the tissue-repair-focused use case. The concept is research-driven rather than a validated clinical protocol. Robust randomized human trials of the combination for tissue-repair indications are not available in the published literature.

Where both stand with FDA

In September 2023, FDA placed both BPC-157 and TB-500 in Category 2, primarily because the human safety and efficacy data for each — at the standard required for 503A compounding eligibility — was not yet available. In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list. FDA removed BPC-157 and TB-500 from Category 2 on April 22, 2026, after their nominations were withdrawn. As of September 14, 2026, neither peptide is in any FDA 503A category, and neither is on the 503A bulks list. As of September 2026, FDA has not made a final decision on BPC-157 or TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted separately on each. Both votes were 8 yes, 6 no, and 1 abstention to recommend adding the peptide to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action.

Who asks about it

People come to this topic when they have heard the BPC-157 + TB-500 combination described in tissue-repair contexts and want to understand the rationale. The honest summary is that the mechanistic complementarity argument is reasonable, the underlying preclinical research is real, and robust human trials of the combination have not been published.

What to know before considering it

Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. People with persistent tissue-injury complaints should be evaluated by an appropriate physician — orthopedist, sports medicine physician, or primary care — using established diagnostic and treatment pathways.

The Halftime POV

BPC-157 and TB-500 are two of the peptides most often discussed together in a recovery context. Whether to combine them is a licensed physician's decision after reviewing your labs. The human trial evidence for the combination is still limited, and we are watching FDA's final decision closely.

---

Related reading:

• BPC-157 for tissue repair and recovery: the evidence
• TB-500 for tissue repair: what the research shows
• BPC-157 and the FDA: Category 2 status and what comes next
• TB-500 regulatory status: Category 2 and the path forward

FAQ

Q: Why are BPC-157 and TB-500 often discussed together? A: Their proposed mechanisms are complementary. BPC-157 has been investigated for promoting angiogenesis and supporting mucosal and matrix-level tissue repair. TB-500 has been investigated for actin regulation, cell migration, and inflammation modulation. The hypothesis behind pairing them is that the two mechanisms address different stages of the repair process. Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness.

Q: What is the RECOVER protocol concept? A: RECOVER is a framing used in peptide-protocol discussions to describe the combination of BPC-157 and TB-500 in tissue-repair contexts. It is a research-driven concept rather than a validated clinical protocol. Whether to combine them is a licensed physician's decision after reviewing your labs.

Q: What is the regulatory status of BPC-157 and TB-500? A: As of September 2026, FDA has not made a final decision on BPC-157 or TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted separately on each. Both votes were 8 yes, 6 no, and 1 abstention to recommend adding the peptide to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness.

---

Disclaimer

As of September 2026, FDA has not made a final decision on BPC-157 or TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted separately on each. Both votes were 8 yes, 6 no, and 1 abstention to recommend adding the peptide to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. This article is educational only and is not medical advice.

Get started

We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.

---

Sources

• Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract. Current Pharmaceutical Design, 2018.
• Crockford D, et al. Thymosin β4: structure, function, and biological properties. Annals of the New York Academy of Sciences, 2010.

---

This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.